Journal
JOURNAL OF PATHOLOGY
Volume 219, Issue 1, Pages 1-2Publisher
WILEY
DOI: 10.1002/path.2593
Keywords
HER2; erbB2; CEP17; polysomy; amplification; herceptin
Ask authors/readers for more resources
A recent paper by Marchio and colleagues indicated that true polysomy of chromosome 17 is rare and that coincident CEP 17 centromere amplification may account for its overestimation in FISH testing for HER2 amplification, with a treat/not treat decision as the final important readout. Here the importance of relating HER2 copy number to cell count rather than a ratio with CEP17 is emphasized. This is central to ensuring that all who may respond to potentially life-saving treatment with herceptin/lapatininib are not denied these drugs. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available